Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
Brief Summary: Disease and Stage: naïve metastatic kidney cancer.

A multicenter, randomized, a Phase 2 BIOmarker driven trial with Nivolumab and Ipilimumab or VEGFR tKi in naïve metastatic Kidney cancer


Options:
A: Arm Label: Arm S: Nivolumab + Sunitinib; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Drug: Sunitinib | Arm Label: Arm P: Nivolumab + Pazopanib; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Pazopanib | Arm Label: Arm I-1: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm I-3: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm IN-3: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm I-1: Nivolumab + Ipilimumab, Arm I-3: Nivolumab + Ipilimumab, Arm IN-3: Nivolumab+Ipilimumab, Arm P: Nivolumab + Pazopanib, Arm S: Nivolumab + Sunitinib | Intervention Type: BIOLOGICAL; Name: Pazopanib; Assigned to Arm(s): Arm P: Nivolumab + Pazopanib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Arm S: Nivolumab + Sunitinib | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm I-1: Nivolumab + Ipilimumab, Arm I-3: Nivolumab + Ipilimumab, Arm IN-3: Nivolumab+Ipilimumab
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon Alfa | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: CCI-779 | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Interferon Alfa and CCI-779 | Intervention Type: DRUG; Name: Interferon Alfa; Assigned to Arm(s): A | Intervention Type: DRUG; Name: CCI-779; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Interferon Alfa and CCI-779; Assigned to Arm(s): C
C: Arm Label: ccRCC molecular subgroup 1: 1A; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab | Arm Label: ccRCC molecular subgroup 1: 1B; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: ccRCC molecular subgroup 4: 4A; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab | Arm Label: ccRCC molecular subgroup 4: 4B; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: ccRCC molecular subgroup 2: 2C; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Sunitinib | Arm Label: ccRCC molecular subgroup 2: 2B; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: ccRCC molecular subgroup 3: 3B; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: ccRCC molecular subgroup 3: 3C; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Sunitinib | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): ccRCC molecular subgroup 1: 1A, ccRCC molecular subgroup 1: 1B, ccRCC molecular subgroup 2: 2B, ccRCC molecular subgroup 3: 3B, ccRCC molecular subgroup 4: 4A, ccRCC molecular subgroup 4: 4B | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): ccRCC molecular subgroup 1: 1B, ccRCC molecular subgroup 2: 2B, ccRCC molecular subgroup 3: 3B, ccRCC molecular subgroup 4: 4B | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): ccRCC molecular subgroup 2: 2C, ccRCC molecular subgroup 3: 3C | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): ccRCC molecular subgroup 2: 2C, ccRCC molecular subgroup 3: 3C
D: Arm Label: tivozanib (AV-951); Type: EXPERIMENTAL; Interventions: Drug: tivozanib (AV-951) | Arm Label: sorafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib | Intervention Type: DRUG; Name: tivozanib (AV-951); Assigned to Arm(s): tivozanib (AV-951) | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): sorafenib

Answer: C